SEATTLE, WA, November 26, 2024 — Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of CAR-T cells, today announced that members of management will participate in a fireside chat and 1×1 investor meetings at the 7th Annual Evercore ISI HealthCONx Conference, which will take place at the Loews Hotel in Coral Gables, Florida, December 3 – 5, 2024.
Fireside Chat Date/Time: Thursday, December 5, 2024, 10:25 a.m. ET
A live webcast link may be accessed HERE.
Meetings: To be scheduled with conference representatives or directly with Umoja
About Umoja Biopharma
Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR-T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit umoja-biopharma.com.
Investors
Grace Kim, Ph.D.
Head of Investor Relations
grace.kim@umoja-biopharma.com
Media
Matt Wright
Real Chemistry
mwright@realchemistry.com